Furthermore, this observation resonates with the superior efficacy of PPARγ agonist pioglitazone over sulfonylureas and metformin in patients with a distinct subset of diabetes characterized by severe insulin‐resistant diabetes.13 This evidence concerns the gene PPARG and insulin-resistant diabetes mellitus.